References
  1. Alsukait SF, Alshamlan NM, Alhalees ZZ, et al. Topical corticosteroids knowledge, attitudes, and practices of primary care physicians. Saudi Med J 2017; 38:662–5.
  2. Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm 2008; 68:453–66.
  3. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54:1–15.
  4. Cornell RC. Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay. Int J Dermatol 1992; 31 Suppl 1:38–40.
  5. Haria M, Balfour JA. Methylprednisolone Aceponate. Clin Immunother 1995; 3:241–53.
  6. McEvoy G, Miller J, Snow E, et al., eds. Metronidazole. In: AHFS Drug Information. Bethesda, MD, American Society of Health-System Pharmacists, 2004; 3314–20.
  7. Kirkland R, Pearce DJ, Balkrishnan R, Feldman SR. Critical factors determining the potency of topical corticosteroids. J Dermatolog Treat 2006; 17:133–5.
  8. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. Drugs 1988; 36:51–61.
  9. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin 2010; 26:633–40.
  10. Humbert P, Guichard A. The topical corticosteroid classification called into question: towards a new approach. Exp Dermatol 2015; 24:393–5.
  11. Green C, Colquitt J, Kirby J, et al. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess (Rockv) 2004; 8:iii,iv, 1-120.
  12. Fusaro RM. Flexible classification for the clinical potency of topical corticosteroid proprietaries. Drug Intell Clin Pharm 1988; 22:412–5.
  13. Oakley A. Topical steroid. DermNet NZ. 2016. Available at: https://dermnetnz.org/topics/topical-steroid/ (accessed on Jan 17, 2022).
  14. Kerscher M, Williams S, Lehmann P. Topical Treatment with Glucocorticoids. In: Handbook of Atopic Eczema (Ring J, Przybilla B, Ruzicka T, eds). Berlin, Heidelberg, Springer Berlin Heidelberg, 2006; 477–91.
  15. Camarasa JG, Giménez-Arnau A. Corticosteroids: topical. In: European Handbook of Dermatological Treatments (Katsambas AD, Lotti TM, eds). Berlin, Heidelberg, Springer Berlin Heidelberg, 2003; 731–8.
  16. Keida T, Hayashi N, Kawashima M. Application of the Food and Drug Administration (FDA) bioequivalent guidance of topical dermatological corticosteroid in yellow-skinned Japanese population: Validation study using a chromameter. J Dermatol 2006; 33:684–91.
  17. Kanfer I, Tettey-Amlalo RNO, Au WL, Hughes-Formella B. Assessment of topical dosage forms intended for local or regional activity. In: Generic Drug Product Development: Specialty Dosage Forms (Shargel L, Kanfer I, eds). New York, NY, Informa Healthcare USA, Inc., 2016; 54–103.
  18. Olsen EA. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol 1991; 127:197–201.
  19. Stoughton RB, Wullich K. The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity? Arch Dermatol 1989; 125:1509–11.
  20. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009; 79:135–40.
  21. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985; 121:63–7.
  22. US Food and Drug Administration. Guidance for Industry: Topical Dermatologic Corticosteroids—In Vivo Bioequivalence; FDA: Silver Spring, MD, USA, 1995. Available at: https://www.fda.gov/media/70931/download (accessed on Jan 17, 2022).
  23. Topical corticosteroids. In: British National Formulary, 78th ed. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, 2019; 1241–2.
  24. Topical Steroid Potencies. Available at: https://www.empr.com/home/clinical-charts/topical-steroid-potencies/ (accessed on Jan 17, 2022).
  25. Allenby CF, Sparkes CG. Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases. Br J Dermatol 1981; 104:179–83.
  26. Zvidzayi M, Rath S, Bon C, et al. A Novel Approach to Assess the Potency of Topical Corticosteroids. Pharmaceutics 2021; 13.
  27. Kanfer I, Maibach H. The Vasoconstrictor Assay (VCA): Then and Now. In: Drug Delivery Approaches: Perspectives from Pharmacokinetics and Pharmacodynamics (Berner B, Gordi T, Benson H, Roberts M, eds). Hoboken, NJ, John Wiley & Sons, Inc., 2021.
  28. Kanfer I. Methods for the Assessment of Bioequivalence of Topical Dosage Forms: Correlations, Optimization Strategies, and Innovative Approaches. In: Topical Drug Bioavailability, Bioequivalence, and Penetration (Shah VP, Maibach HI, Jenner J, eds), 2nd ed. New York, NY, Springer, 2014; 113–51.
  29. Bonate PL. Recommended reading in population pharmacokinetic pharmacodynamics. AAPS J 2005; 7:E363–73.
  30. Ozdin D, Sharma N, Lujan-Zilbermann J, et al. Revisiting FDA’s 1995 Guidance on bioequivalence establishment of topical dermatologic corticosteroids: new research based recommendations. J Pharm Pharm Sci 2018; 21:413–28.
  31. Mentré F, Gomeni R. A Two-Step Iterative Algorithm For Estimation In Nonlinear Mixed-Effect Models With An Evaluation In Population Pharmacokinetics. J Biopharm Stat 2007; 5:141–58.
  32. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6:429–53.
  33. Singh G, Adams W, Lesko L, et al. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther 1999; 66:346–57.